Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873381 | 0.79 | PTGDR2 (0.53) | MEN1KMT2APTGDR2KDM4EPOLB | |
| SCHEMBL15796727 | 0.78 | COMT (0.42) | GAACOMTCYP1A2 | |
| SCHEMBL7818030 | 0.77 | PTGDR2 (0.37) | MEN1KMT2APTGDR2ADAMTS5KDM4E | |
| SCHEMBL1843654 | 0.76 | COMT (0.39) | GAACOMTCYP1A2 | |
| SCHEMBL1158268 | 0.76 | PTGDR2 (0.40) | MEN1KMT2APTGDR2ADAMTS5KDM4E | |
| SCHEMBL6739260 | 0.76 | PTGDR2 (0.40) | MEN1KMT2APTGDR2ADAMTS5KDM4E | |
| SCHEMBL11150044 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2APTGDR2KDM4EPOLB | |
| SCHEMBL5026007 | 0.76 | CYP1A2 (0.54) | MEN1KMT2AALDH1A1MAPTCYP1A2 | |
| SCHEMBL27860995 | 0.75 | PTGDR2 (0.36) | MEN1KMT2APTGDR2ADAMTS5ALDH1A1 | |
| SCHEMBL10360134 | 0.74 | PTGDR2 (0.39) | MEN1KMT2APTGDR2ADAMTS5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100136300-A1 | CURABLE COMPOSITION, INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, METHOD OF PRODUCING PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE AND OXETANE COMPOUND | FUJIFILM CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| US-7709550-B2 | Ink composition, inkjet recording method, printed material, process for producing lithographic printing plate, and lithographic printing plate | FUJIFILM CORPORATION (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7219988-B2 | Water-soluble phthalocyanine compound-containing ink for ink jetting, ink jet recording method and method for improving ozone gas discoloration of colored image material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20070052790-A1 | Ink composition, inkjet recording method, printed material, process for producing lithographic printing plate, and lithographic printing plate | FUJI PHOTO FILM CO., LTD. | 2007-03-08 | — | — | US | disclosed |
| US-20070049651-A1 | Curable composition, ink composition, inkjet recording method, printed material, method of producing planographic printing plate, planographic printing plate, and oxcetane compound | FUJI PHOTO FILM CO., LTD. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136300-A1 | CURABLE COMPOSITION, INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, METHOD OF PRODUCING PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE AND OXETANE COMPOUND | CCNT1, ACVR2B, ACVR1B | MEN1 2235/4885KMT2A 726/4885PTGDR2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.